1887

Journal of Medical Microbiology logo

Volume 58, Issue 6

An evaluation of two commercially available ELISAs and one in-house reference laboratory ELISA for the determination of human anti-rabies virus antibodies Free

Abstract

The envelope glycoprotein G of rabies virus in vaccines induces the production of neutralizing antibodies important in the protection against the disease. The measurement of anti-envelope glycoprotein antibodies is a good predictor of the degree of humoral immunity in people during anti-rabies treatment or after vaccination. Several assays exist for the serological determination of antibody protection against rabies virus infection. Antibody neutralization by the rapid fluorescent focus inhibition test (RFFIT) or the fluorescent antibody virus neutralization (FAVN) test is currently the gold standard. Performance of the highly complex RFFIT and FAVN tests, however, requires specialized reference laboratories with expertise with this assay. Although not widely used, ELISA test kits are available and may be an additional option for testing that is more accessible. The aim of the present study was to evaluate available ELISA assays for the determination of anti-rabies antibodies. We compared the Bio-Rad Platelia Rabies II ELISA, DRG Rabies Virus IgG Ab ELISA and Focus Diagnostics Rabies Antibody Detection by ELISA to RFFIT. Bland–Altman plots comparing the Bio-Rad Platelia assay and the Focus Diagnostics assay to RFFIT showed a low degree of variability between the ELISA assays and RFFIT results except in samples with high RFFIT values. The agreement, sensitivity and specificity of Bio-Rad Platelia Rabies II ELISA when compared to RFFIT were 95.1 %, 94.1 % and 95.8 %, respectively. The DRG Rabies assay compared to RFFIT had an agreement of 77.7 %, a sensitivity of 86.7 % and a specificity of 69.4 %. The agreement, sensitivity and specificity of Focus Diagnostics Rabies Detection by ELISA when compared to RFFIT were 82.2 %, 91.7 % and 73.0 %, respectively. Overall, the Bio-Rad Platelia assay showed higher accuracy and specificity than either the DRG or Focus assays. All of these ELISAs, however, measure all antibody types and do not discriminate the neutralizing antibodies as measured by functional assays (RFFIT and FAVN) and cannot be relied upon to predict the neutralizing activity of the sera. The results of this study offer insight into the availability of alternative, less-complex methods to monitor rabies antibody titres in at-risk individuals following vaccination.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): CI, confidence interval , FAVN, fluorescent antibody virus neutralization , RFFIT, fluorescent focus inhibition test and WHO, World Health Organization
SGM
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.006064-0
2009-06-01
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/jmm/58/6/806.html?itemId=/content/journal/jmm/10.1099/jmm.0.006064-0&mimeType=html&fmt=ahah

References

  1. Atanasiu P., Perrin P. 1979; Micromethod for rabies antibody detection by immunoenzymatic assay with Staphylococcus protein A. Ann Microbiol (Paris 130:257–268
     [Google Scholar]
  2. Bland J. M., Altman D. G. 1995; Comparing methods of measurement: why plotting difference against standard method is misleading. Lancet 346:1085–1087 [CrossRef]
     [Google Scholar]
  3. Briggs D. J., Smith J. S., Mueller F. L., Schwenke J., Davis R. D., Gordon C. R., Schweitzer K., Orciari L. A., Yager P. A., Rupprecht C. E. 1998; A comparison of two serological methods for detecting the immune response after rabies vaccination in dogs and cats being exported to rabies-free areas. Biologicals 26:347–355 [CrossRef]
     [Google Scholar]
  4. CDC 1999; Human rabies prevention – United States, 1999. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 48:1–21
     [Google Scholar]
  5. CDC 2006; Compendium of Animal Rabies Prevention and Control; 2006; National Association of State Public Health Veterinarians, Inc. (NASPHV). MMWR Morb Mortal Wkly Rep 55:1–8
     [Google Scholar]
  6. Favoretto S. R., de Mattos C. C., de Morais N. B., Carrieri M. L., Rolim B. N., Silva L. M., Rupprecht C. E., Durigon E. L., de Mattos C. A. 2006; Rabies virus maintained by dogs in humans and terrestrial wildlife. Ceara State; Brazil: Emerg Infect Dis 12, 1978–1981 [CrossRef]
  7. Feyssaguet M., Dacheux L., Audry L., Compoint A., Morize J. L., Blanchard I., Bourhy H. 2007; Multicenter comparative study of a new ELISA, PLATELIA RABIES II, for the detection and titration of anti-rabies glycoprotein antibodies and comparison with the rapid fluorescent focus inhibition test (RFFIT) on human samples from vaccinated and non-vaccinated people. Vaccine 25:2244–2251 [CrossRef]
     [Google Scholar]
  8. Fishbein D. B., Robinson L. E. 1993; Rabies. N Engl J Med 329:1632–1638 [CrossRef]
     [Google Scholar]
  9. Fleiss J. L. 1981 Statistical Methods for Rates and Proportions , 2nd edn. New York: Wiley;
     [Google Scholar]
  10. Knobel D. L., Cleaveland S., Coleman P. G., Fèvre E. M., Meltzer M. I., Miranda M. E., Shaw A., Zinsstag J., Meslin F. X. 2005; Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ 83:360–368
     [Google Scholar]
  11. Krause R., Bago Z., Revilla-Fernandez S., Loitsch A., Allerberger F., Kaufmann P., Smolle K. H., Brunner G., Krejs G. J. 2005; Travel-associated rabies in Austrian man. Emerg Infect Dis 11:719–721
     [Google Scholar]
  12. Krebs J. W., Mandel E. J., Swerdlow D. L., Rupprecht C. E. 2005; Rabies surveillance in the United States during 2004. J Am Vet Med Assoc 227:1912–1925 [CrossRef]
     [Google Scholar]
  13. Mandell G. L., Douglas R. G., Bennett J. E., Dolin R. 2005 Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases , 6th edn. Philadelphia and London: Churchill Livingstone;
     [Google Scholar]
  14. Meslin F. X., Fishbein D. B., Matter H. C. 1994; Rationale and prospects for rabies elimination in developing countries. Curr Top Microbiol Immunol 187:1–26
     [Google Scholar]
  15. Murray K. O., Arguin P. M. 2000; Decision-based evaluation of recommendations for preexposure rabies vaccination. J Am Vet Med Assoc 216:188–191 [CrossRef]
     [Google Scholar]
  16. Perrin P., Versmisse P., Delagneau J. F., Lucas G., Rollin P. E., Sureau P. 1986; The influence of the type of immunosorbent on rabies antibody EIA; advantages of purified glycoprotein over whole virus. J Biol Stand 14:95–102 [CrossRef]
     [Google Scholar]
  17. WHO 2005; WHO Expert Consultation on rabies. World Health Organ Tech Rep Ser 931:1–88
     [Google Scholar]
  18. Wilde H., Briggs D. J., Meslin F. X., Hemachudha T., Sitprija V. 2003; Rabies update for travel medicine advisors. Clin Infect Dis 37:96–100 [CrossRef]
     [Google Scholar]
  19. Wright E., Temperton N. J., Marston D. A., McElhinney L. M., Fooks A. R., Weiss R. A. 2008; Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison. J Gen Virol 89:2204–2213 [CrossRef]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.006064-0
Loading
An evaluation of two commercially available ELISAs and one in-house reference laboratory ELISA for the determination of human anti-rabies virus antibodies
J. Med. Microbiol. 58, 806 (2009); https://doi.org/10.1099/jmm.0.006064-0
/content/journal/jmm/10.1099/jmm.0.006064-0
/content/journal/jmm/10.1099/jmm.0.006064-0
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error